According to our analyses, we believed RelB was a potential molecular biomarker in cancer immunotherapy in most cancer types including ACC, BRCA, ESCA, KIPAN, COAD, PRAD, STAD, HNSC, LUSC, LUAD, LIHC, BLCA, THCA, OV, PAAD and CHOL. The gene discussed is RELB; the disease is cancer.